Want to see INIS full AI Analyst Report?
INIS Stock Chart & Stats
$0.06
<$0.01(12.90%)
At close: 4:00 PM EDT
$0.06
<$0.01(12.90%)
Day’s Range― - ―
52-Week Range$0.05 - $0.11
Previous CloseN/A
Volume45.00K
Average Volume (3M)97.60K
Market Cap
$32.17M
Enterprise Value$45.05
Total Cash (Recent Filing)$1.20M
Total Debt (Recent Filing)$9.21M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1723.63
Shares Outstanding529,154,200
10 Day Avg. Volume65,048
30 Day Avg. Volume97,599
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)8.74
Price to Sales (P/S)2.47
P/FCF Ratio375.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exposure To Specialized Isotope MarketsThe company serves specialized markets requiring isotope expertise, controlled-material handling, and regulatory compliance. These capabilities can create operational barriers and support durable customer relevance across medical and industrial applications.
Technology Portfolio ExpansionAdding imaging platforms, software, intellectual property, and regulatory approvals broadens the technology base and may improve the company’s competitive position. Milestone-linked consideration also aligns part of the acquisition cost with future regulatory and sales performance.
Extended Financing MaturitiesLonger maturities reduce immediate redemption and repayment pressure, giving management more time to execute its operating plans and allocate cash. The amendments improve capital-planning flexibility, although they do not eliminate the underlying financing obligations.
Bears Say
Severe Profitability DeteriorationDeep operating losses and an unusually large net loss weaken internal funding capacity and raise concerns about earnings quality. Unless profitability recovers, the company may remain dependent on financing and have limited flexibility to invest in growth.
High Balance Sheet LeverageElevated leverage leaves limited protection against operational setbacks and increases the importance of refinancing or conversion arrangements. A highly burdened capital structure can constrain investment, amplify losses, and divert future resources toward creditors.
Inconsistent Cash GenerationRecent cash consumption indicates that operations are not consistently self-funding. Although positive cash flow occurred in some earlier years, substantial year-to-year volatility reduces confidence in funding ongoing operations, technology investment, and obligations without external capital.
International Isotopes News
INIS FAQ
What was International Isotopes’s price range in the past 12 months?
International Isotopes lowest stock price was $0.04 and its highest was $0.11 in the past 12 months.
What is International Isotopes’s market cap?
International Isotopes’s market cap is $32.17M.
When is International Isotopes’s upcoming earnings report date?
International Isotopes’s upcoming earnings report date is Nov 17, 2026 which is in 92 days.
How were International Isotopes’s earnings last quarter?
International Isotopes released its earnings results on Aug 13, 2026. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is International Isotopes overvalued?
According to Wall Street analysts International Isotopes’s price is currently Overvalued.
Does International Isotopes pay dividends?
International Isotopes does not currently pay dividends.
What is International Isotopes’s EPS estimate?
International Isotopes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does International Isotopes have?
International Isotopes has 529,154,200 shares outstanding.
What happened to International Isotopes’s price movement after its last earnings report?
International Isotopes reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.688%.
Which hedge fund is a major shareholder of International Isotopes?
Currently, no hedge funds are holding shares in INIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
International Isotopes
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radiochemicals. Its operations are structured into five key divisions: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products. The Nuclear Medicine Standards segment is responsible for creating various sources and standards essential for single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging, accurate patient positioning, and for calibrating or testing the performance of dose-measuring equipment within the nuclear pharmacy industry. This segment's product range includes flood sources, dose calibrators, rod sources, flexible and rigid rulers, precision spot and pen point markers, and numerous custom-designed items. The Cobalt Products division processes bulk cobalt, fabricates cobalt capsules for use in radiation therapy and diverse industrial applications, and is involved in the recycling of depleted cobalt sources. Through its Radiochemical Products segment, Radnostix develops and supplies a variety of highly pure radiochemicals, along with the generic drug product sodium iodide I-131, serving medical, industrial, and research applications. The Radiological Services segment offers specialized services such as the safe disposal of flood sources and the intricate processing of gemstones. Finally, the Fluorine Products segment focuses on producing small-scale, high-purity fluoride gas samples for qualification in various industrial applications. It also undertakes the development of critical laboratory and analytical processes required to support a planned uranium de-conversion and fluorine extraction facility. Radnostix, Inc. distributes its products directly to end-users as well as through a network of distributors. The company was founded in 1995 and is headquartered in Idaho Falls, Idaho.
Technical Analysis
Ownership Overview
13.32% Insiders
<0.01% Other Institutional Investors
86.68% Public Companies and
Individual Investors